Amphastar Pharma (AMPH) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amphastar Pharmaceuticals (AMPH) PT Raised to $17 at BMO Capital on 3Q Report; 'Awaiting Execution With Key Pipeline Opportunities'
November 10, 2017 9:29 AM ESTBMO Capital raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $17.00 (from $16.00) while maintaining a Market Perform rating, following the company's third quarter earnings report.
Analyst Gary Nachman notes an improved price targets, as the company reported third quarter earnings per share and... More
Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Jefferies
November 9, 2017 8:28 AM ESTJefferies raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $19.00) while maintaining a Buy rating.
Analyst David Steinberg notes revenue for the quarter came in slightly above their estimates at $57.9M largely due to better than expected Naloxone... More
Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Piper Jaffray
November 9, 2017 7:52 AM ESTPiper Jaffray raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $19.00) while maintaining an Overweight rating.
Analyst David Amsellem notes solid performance from the base business. The analyst believes there is still room for meaningful value creation in the context of an EV/2018E EBITDA of 10x-11x.
... More